ArticleBJU international2025
Survival after trimodal therapy in octogenarians with organ-confined urothelial bladder cancer.
Article in BJU international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Perioperative outcomes following open radical cystectomy in the setting of locally advanced bladder cancer.International urology and nephrology · 2026Observational
- ASO Author Reflections: Quantifying the Unseen: Years of Life Lost as a Patient-Centered Metric in Advanced Bladder Cancer.Annals of surgical oncology · 2026Article
- Years of Life Lost in Patients with Muscle-Invasive and Metastatic Bladder Cancer.Annals of surgical oncology · 2026Article
- Extent of Pelvic Lymph Node Dissection at Partial Cystectomy: Effect on Cancer-Specific Mortality.International journal of urology : official journal of the Japanese Urological Association · 2026Article
- The Effect of Pelvic Lymph Node Dissection on Cancer-Specific Mortality in Partial Cystectomy According to Eligibility Criteria.Annals of surgical oncology · 2026Article
- Consolidation enfortumab vedotin and pembrolizumab after cisplatin induction in metastatic urothelial cancer: Outcomes of complete response and bladder preservation.The Journal of international medical research · 2026Article
- Development and external validation of a nomogram predicting cancer-specific mortality-free survival after trimodal therapy in muscle-invasive bladder cancer.World journal of urology · 2026Article
- Oncological outcomes after non-surgical management versus radical cystectomy in non-organ-confined non-urothelial bladder cancer.International urology and nephrology · 2025Article
- Contemporary outcomes in non-muscle-invasive bladder cancer: a large European multicentre study.BJU international · 2025Article
- Effect of neoadjuvant chemotherapy on years of life lost in radical cystectomy-treated T2N0M0 bladder cancer patients.World journal of urology · 2025Article
- Cancer-Specific Mortality of Partial Cystectomy Versus Radical Cystectomy in T2N0M0 Urothelial Bladder Cancer.Annals of surgical oncology · 2025Article
- Cancer-Specific Survival of Trimodal Therapy Versus Radical Cystectomy in T2N0M0 Non-Urothelial Bladder Cancer.Journal of surgical oncology · 2025Article
- Multiparametric MRI lesion dimension as a significant predictor of positive surgical margins following laparoscopic radical prostatectomy for transitional zone prostate cancer.World journal of urology · 2025Article
- Optimizing treatment selection: outcomes of radical cystectomy in patients eligible for trimodal therapy.World journal of urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIt is not known whether cancer-specific mortality (CSM) differences distinguish radical cystectomy (RC) from trimodal therapy (TMT) in octogenarians harbouring organ-confined (T2N0M0) urothelial cancer of the urinary bladder (UCUB).
methodsWithin the Surveillance, Epidemiology, and End Results database (2004-2021), CSM and other-cause mortality (OCM) rates were computed in octogenarian patients with organ-confined UCUB undergoing either TMT or RC. Smoothed cumulative incidence plots depicted 5-year CSM and OCM rates according to RC vs TMT. Competing risks regression (CRR) models were fitted, adjusting for age, gender, and race/ethnicity. Nearest-neighbour 1:1 propensity-score matching (PSM) for age and gender was also applied. Sensitivity analyses were additionally performed, focusing on White patients.
resultsOf 2335 octogenarian patients with T2N0M0 UCUB, 1562 (66.3%) received TMT and 793 (33.7%) received RC. Of those, 2082 (88.4%) were White. TMT rates increased from 53.5% in 2004 to 82.2% in 2021 (P < 0.001). The 5-year CSM rate was 50.1% for TMT vs 31.1% for RC. After multivariable CRR, TMT independently predicted 1.7-fold higher CSM (P < 0.001). After additional PSM, TMT also independently predicted 1.7-fold higher CSM (P < 0.001). In sensitivity analyses exclusively focusing on White patients, almost identical results were recorded.
conclusionRates of TMT have nearly doubled in octogenarian patients with organ-confined UCUB in recent years; however, CSM rates after TMT are also nearly twice as high as those observed after RC. It is crucial to communicate these observations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.